search
Back to results

Guanidinoacetic Acid With Creatine Compared With Creatine Alone for Tissue Bioenergetics, Hyperhomocysteinemia and Exercise Performance

Primary Purpose

Energy Metabolism

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
GAA-creatine
Creatine
Sponsored by
University of Novi Sad, Faculty of Sport and Physical Education
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Energy Metabolism

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • men age 18-45 years
  • BMI 18.5-24.9 kg/m2
  • physically active (> 150 min per week)
  • free of known disease
  • must be able to give written informed consent

Exclusion Criteria:

  • serum homocysteine > 15 µmol/L
  • use of dietary supplement (> 1 month)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Mixture GAA-creatine

    Creatine

    Arm Description

    Mixture of guanidinoacetic acid and creatine monohydrate

    Creatine monohydrate

    Outcomes

    Primary Outcome Measures

    Brain creatine
    Rise in brain creatine levels

    Secondary Outcome Measures

    Vastus medialis creatine
    Rise in vastus medialis creatine creatine levels

    Full Information

    First Posted
    November 17, 2017
    Last Updated
    May 3, 2018
    Sponsor
    University of Novi Sad, Faculty of Sport and Physical Education
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03350282
    Brief Title
    Guanidinoacetic Acid With Creatine Compared With Creatine Alone for Tissue Bioenergetics, Hyperhomocysteinemia and Exercise Performance
    Official Title
    Guanidinoacetic Acid With Creatine Compared With Creatine Alone for Tissue Bioenergetics, Hyperhomocysteinemia and Exercise Performance: a Randomized Double-blind Superiority Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    December 1, 2016 (Actual)
    Primary Completion Date
    May 1, 2018 (Actual)
    Study Completion Date
    May 1, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Novi Sad, Faculty of Sport and Physical Education

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Co-administration of creatine and guanidinoacetic acid (GAA) has been recently put forward as an advanced dietary strategy to optimize tissue bioenergetics. The investigators hypothesized that creatine-GAA mixture would result in more powerful rise in brain and skeletal muscle creatine, as compared to creatine supplementation alone.
    Detailed Description
    Targeting energy-demanding tissues in health and disease continues to be a challenging task in human nutrition and biomedicine. Impaired bioenergetics accompanies many different conditions, including cardiometabolic diseases, neurodegenerative disorders or high-intensity exercise, with various dietary interventions developed to restore cellular energy. Creatine is recognized as a beneficial and safe energy-boosting agent in both athletic and clinical environments. However, its effectiveness in specific conditions seems to be fairly restrained due to its limits in transportability and performance. Guanidinoacetic acid (GAA), a metabolic precursor of creatine, appears as a novel energy-enhancing supplement, with GAA being superior to creatine in facilitating creatine concentrations in the human brain and skeletal muscle. This perhaps happens due to GAA interaction with cellular transporters previously dismissed as untargetable carriers by other similar therapeutics. On the other hand, GAA loading remains under scrutiny due to its hyperhomocysteinemia-inducing potential, and possible neurotoxic effects. Co-administration of creatine and GAA has been recently proposed as a better strategy comparing to administration of each compound per se. Besides providing a competitive advantage for enhanced levels of tissue creatine, GAA-creatine mixture might also diminish side effects related to isolated GAA administration. However, no human studies so far evaluated the effects of this mixture. In the present study, the investigators compared the impact of 4-week co-administration of GAA and creatine vs. creatine administration alone on serum biomarkers, exercise performance and tissue bioenergetics in healthy young men.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Energy Metabolism

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    14 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Mixture GAA-creatine
    Arm Type
    Experimental
    Arm Description
    Mixture of guanidinoacetic acid and creatine monohydrate
    Arm Title
    Creatine
    Arm Type
    Active Comparator
    Arm Description
    Creatine monohydrate
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    GAA-creatine
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Creatine
    Primary Outcome Measure Information:
    Title
    Brain creatine
    Description
    Rise in brain creatine levels
    Time Frame
    Baseline vs 4-week follow up
    Secondary Outcome Measure Information:
    Title
    Vastus medialis creatine
    Description
    Rise in vastus medialis creatine creatine levels
    Time Frame
    Baseline vs 4-week follow up

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: men age 18-45 years BMI 18.5-24.9 kg/m2 physically active (> 150 min per week) free of known disease must be able to give written informed consent Exclusion Criteria: serum homocysteine > 15 µmol/L use of dietary supplement (> 1 month)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Sergej Ostojic, MD, PhD
    Organizational Affiliation
    University of Novi Sad
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    The data will be shared via institutional repository
    IPD Sharing Time Frame
    Data will be available from January 2018
    Citations:
    PubMed Identifier
    28460226
    Citation
    Ostojic SM. Co-administration of creatine and guanidinoacetic acid for augmented tissue bioenergetics: A novel approach? Biomed Pharmacother. 2017 Jul;91:238-240. doi: 10.1016/j.biopha.2017.04.075. Epub 2017 Apr 28.
    Results Reference
    background
    PubMed Identifier
    30170305
    Citation
    Semeredi S, Stajer V, Ostojic J, Vranes M, Ostojic SM. Guanidinoacetic acid with creatine compared with creatine alone for tissue creatine content, hyperhomocysteinemia, and exercise performance: A randomized, double-blind superiority trial. Nutrition. 2019 Jan;57:162-166. doi: 10.1016/j.nut.2018.04.009. Epub 2018 May 17.
    Results Reference
    derived

    Learn more about this trial

    Guanidinoacetic Acid With Creatine Compared With Creatine Alone for Tissue Bioenergetics, Hyperhomocysteinemia and Exercise Performance

    We'll reach out to this number within 24 hrs